ImCheck Therapeutics Presents Updates from the EVICTION Trial
ImCheck Therapeutics is set to unveil critical findings from its ongoing EVICTION trial during a poster presentation at an important annual meeting. This informative event, hosted by the Society for Immunotherapy of Cancer, promises valuable insights for professionals in the oncology field.
Overview of the EVICTION Trial
The EVICTION study investigates the potential of ICT01, a humanized monoclonal antibody designed to target butyrophilin 3A (BTN3A). This antibody specifically activates gamma delta T cells in patients suffering from advanced cancer types who have not responded to standard treatments. The upcoming presentations will highlight preliminary results from this trial.
Key Details of the Trial Presentation
Two poster sessions will detail the findings. The first presentation will take place on November 8, focusing on the effectiveness of combining ICT01 with pembrolizumab in treating patients with urothelial cell carcinoma. This study's interim results show promising responses from heavily pretreated individuals.
Another Poster Presentation
The second session, scheduled for November 9, will report on the same combination therapy within a cohort of patients suffering from refractory melanoma. Dr. Stephane Champiat from the University of Texas MD Anderson Cancer Center will present both posters, contributing his expertise to underscore the importance of ICT01.
Details of the Upcoming Presentations
During the poster presentations at the George R. Brown Convention Center, attendees can expect to learn in-depth about ICT01’s dual mechanism of action. This therapy aims to reshape the body’s immune response against malignant cells, shedding light on innovative treatment pathways that could change clinical practices.
What Makes ICT01 Unique?
ICT01's remarkable potential lies in its capacity to not only activate specific immune cells but also enhance their ability to infiltrate tumors. Through previous studies, it has been demonstrated that this antibody effectively encourages T cell activation, which plays a crucial role in mounting a sustained immune attack against tumors. Such findings are particularly relevant for the treatment of various solid tumors.
About ImCheck Therapeutics
ImCheck Therapeutics is pioneering the development of next-generation immunotherapeutic antibodies aimed at butyrophilins, a new class of immunomodulatory proteins. Their lead program, ICT01, exemplifies how these therapies can aid in arming the immune system to fight cancer more effectively than traditional treatments.
Collaboration and Support
Support from leading experts and institutions, like Professor Daniel Olive, has been instrumental in driving forward ImCheck's vision. Their innovative approach is expected to yield substantial breakthroughs in the field of cancer immunotherapy, establishing them as a formidable contender in the industry.
Frequently Asked Questions
What is the EVICTION trial?
The EVICTION trial is an ongoing clinical study evaluating ICT01's effectiveness in patients with refractory solid tumors, assessing safety and efficacy.
What is ICT01?
ICT01 is an innovative monoclonal antibody that selectively activates gamma delta T cells, enhancing the immune response against cancer.
When will the trial data be presented?
The updated data will be presented at the SITC annual meeting from November 6 to 10.
Where can I find more information about the trial?
Additional information can be found on the company’s corporate website following the poster sessions.
Who is presenting the EVICTION trial data?
Dr. Stephane Champiat from the University of Texas MD Anderson Cancer Center will lead the poster presentations on the trial data.
